Wilson's disease presenting alongside bipolar disorder or mania defines a specific clinical scenario requiring a carefully selected treatment approach. This protocol addresses mood stabilisation in patients with confirmed Wilson's disease who are experiencing manic symptoms.
This protocol applies to patients with Wilson's disease who present with mania or carry a diagnosis of bipolar disorder. The coexistence of bipolar disorder with Wilson's disease shapes which treatment agents are considered appropriate first-line options in this setting.
A specific mood stabiliser is recommended as the first-line choice in this scenario. Additional agents addressing psychomotor agitation or anxiety may also be considered as part of the broader management plan. The complete regimen, selection criteria, and monitoring requirements are available in the full structured protocol.
The primary treatment targets are achieving an appropriate serum level of the mood-stabilising agent and obtaining measurable improvement or full resolution of manic symptoms.
DOI: 10.1016/j.jhep.2024.11.007
Lithium is the recommended first-line treatment for mania and hypomania in WD because it is renally excreted and not metabolised by the liver.
Mood stabilisers/lithium carbonate in first line (serum target 0.6-1 mmol/L)
View source ↗